Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
2023 was off to a shockingly great start! We were thrilled to acquire Neovasc, a company with a first-of-its-kind technology to address refractory angina, and are looking forward to driving value for physicians and improving the lives of an underserved patient population. The excitement for our new peripheral product, Shockwave L6, was electrifying and has continued to make waves across the U.S. Shockwave IVL and Coronary IVL became listed by SCAI as a potential therapy option across all U.S. cath labs regardless of surgical backup status. As always, we were further confirming the efficacy and safety of Shockwave IVL across different calcium morphologies through new publications. We highlight these topics and more in our latest PulsePoint Newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
We asked Prof. James Spratt and Dr. Simon Wilson to share their IVL journey since the launch of Shockwave C2 five years ago and their initial experience with the new Shockwave C2+. Regardless of the physicians experience, the overall opinion is the same: “IVL is quick to learn, easy to use, very safe, and effective across a broad range of calcium types that other technologies can’t compete with. It has changed the landscape for calcium modification and the new Shockwave C2+ catheter continues to expand physicians ability to deal effectively and safely with severe calcium in a broader range of patients.” Read more below:
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
A partir de 2 de Maio, a Shockwave Medical está diretamente em Portugal.
Topics: IVL Technology, SWAV News
Desde el 2 de mayo, Shockwave Medical cuenta con un Equipo de Venta Directa en España.
Topics: IVL Technology, SWAV News
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
